uniQure N.V. (QURE)
NASDAQ: QURE · Real-Time Price · USD
18.05
+0.15 (0.84%)
At close: Apr 28, 2026, 4:00 PM EDT
17.80
-0.25 (-1.39%)
Pre-market: Apr 29, 2026, 8:16 AM EDT
uniQure Revenue
In the year 2025, uniQure had annual revenue of $16.10M, down -40.64%. uniQure had revenue of $5.57M in the quarter ending December 31, 2025, with 6.65% growth.
Revenue (ttm)
$16.10M
Revenue Growth
-40.64%
P/S Ratio
70.68
Revenue / Employee
$72,842
Employees
221
Market Cap
1.14B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 16.10M | -11.02M | -40.64% |
| Dec 31, 2024 | 27.12M | 11.28M | 71.17% |
| Dec 31, 2023 | 15.84M | -90.64M | -85.12% |
| Dec 31, 2022 | 106.48M | -417.52M | -79.68% |
| Dec 31, 2021 | 524.00M | 486.49M | 1,296.82% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharming Group | 376.13M |
| Xeris Biopharma Holdings | 291.85M |
| UroGen Pharma | 109.79M |
| Septerna | 45.95M |
| EyePoint | 31.37M |
| Zenas BioPharma | 10.00M |
| Inventiva | 7.94M |
| Aktis Oncology | 6.50M |
QURE News
- 1 day ago - uniQure to Announce First Quarter 2026 Financial Results - GlobeNewsWire
- 18 days ago - UNIQURE DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Encourages uniQure N.V. - GlobeNewsWire
- 26 days ago - UNIQURE DEADLINE APPROACHING: Bragar Eagel & Squire, P.C. Encourages uniQure N.V. - GlobeNewsWire
- 4 weeks ago - QURE SHAREHOLDER NOTICE: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data - PRNewsWire
- 7 weeks ago - This biotech's stock is soaring after a ‘polarizing' FDA official is stepping down - Market Watch
- 7 weeks ago - Federal health officials attacked an Amsterdam-based biotech company seeking approval of a Huntington's disease treatment and accused it of lying - WSJ
- 7 weeks ago - FDA official calls UniQure's gene therapy a 'failed' treatment for Huntington's disease - CNBC
- 7 weeks ago - Sr. FDA official calls Uniqure's Huntington's disease treatment a failure - Reuters